Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Timing of food intake impacts daily rhythms of human salivary microbiota: a randomized, crossover study

  • Collado, María Carmen
  • Engen, Phillip A.
  • Bandin, Cristina
  • Cabrera-Rubio, Raúl
  • Voigt, Robin M.
  • Green, Stefan J.
  • Naqib, Ankur
  • Keshavarzian, Ali
  • Scheer, Frank A. J. L.
  • Garaulet, Marta
The composition of the diet (what we eat) has been widely related to the microbiota profile. However, whether the timing of food consumption (when we eat) influences microbiota in humans is unknown. A randomized, crossover study was performed in 10 healthy normal-weight young women to test the effect of the timing of food intake on the human microbiota in the saliva and fecal samples. More specifically, to determine whether eating late alters daily rhythms of human salivary microbiota, we interrogated salivary microbiota in samples obtained at 4 specific time points over 24 h, to achieve a better understanding of the relationship between food timing and metabolic alterations in humans. Results revealed significant diurnal rhythms in salivary diversity and bacterial relative abundance (i.e., TM7 and Fusobacteria) across both early and late eating conditions. More importantly, meal timing affected diurnal rhythms in diversity of salivary microbiota toward an inverted rhythm between the eating conditions, and eating late increased the number of putative proinflammatory taxa, showing a diurnal rhythm in the saliva. In a randomized, crossover study, we showed for the first time the impact of the timing of food intake on human salivary microbiota. Eating the main meal late inverts the daily rhythm of salivary microbiota diversity which may have a deleterious effect on the metabolism of the host, This work was supported by Spanish Government of Economy and Competitiveness (MINECO) Grants AGL2015-707487-P (to M.C.C.) and SAF2014-52480R; the European Regional Development Fund (ERDF); U.S. National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases Grants R01DK102696 and DK1-R01DK_105072-01A1 (to M.G.), and R01 DK099512 and R01DK105072 (to F.A.J.L.S.); and NIH National, Heart, Lung, and Blood Institute Grants R01 HL094806, R01 HL140574 and R01 HL118601 (to F.A.J.L.S.). F.A.J.L.S. has received speaker fees from Bayer Healthcare, Sentara Healthcare, Philips, and Kellogg Company. The remaining authors declare no conflicts of interest., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Gut Microbiota and Mucosal Immunity in the Neonate

  • Dzidic, Majda
  • Boix-Amorós, Alba
  • Selma Royo, Marta
  • Mira, Alex
  • Collado, María Carmen
Gut microbiota colonization is a complex, dynamic, and step-wise process that is in constant development during the first years of life. This microbial settlement occurs in parallel with the maturation of the immune system, and alterations during this period, due to environmental and host factors, are considered to be potential determinants of health-outcomes later in life. Given that host–microbe interactions are mediated by the immune system response, it is important to understand the close relationship between immunity and the microbiota during birth, lactation, and early infancy. This work summarizes the evidence to date on early gut microbiota colonization, and how it influences the maturation of the infant immune system and health during the first 1000 days of life. This review will also address the influence of perinatal antibiotic intake and the importance of delivery mode and breastfeeding for an appropriate development of gut immunity., The authors would like to acknowledge the European Research Council (ERC) under the European Union’s Horizon 2020 Research and Innovation Programme (ERC Starting Grant, project no. 639226) and the grants AGL2015-707487-P and BIO2015-68711-R from the Spanish Ministerio de Economía, Industria y Competitividad (MINECO). MSR would like to acknowledge the support from the Ayudas para la Contratación de Personal Investigador en Formación (ACIF) program of Generalitat Valenciana with the European Social Fund (ESF)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Impact of Donor Human Milk in the preterm very low birth weight gut transcriptome profile by use of exfoliated intestinal cells

  • Parra Llorca, Anna
  • Gormaz, María
  • Lorente-Pozo, Sheila
  • Cernada, María
  • García-Robles, Ana
  • Torres-Cuevas, Isabel
  • Kuligowski, Julia
  • Collado, María Carmen
  • Serna, Eva
  • Vento, Máximo
[Background] Own mother’s milk (OMM) is the optimal nutrition for preterm infants. However, pasteurized donor human milk (DHM) is a valid alternative. We explored the differences of the transcriptome in exfoliated epithelial intestinal cells (EEIC) of preterm infants receiving full feed with OMM or DHM., [Methods] The prospective observational study included preterm infants ≤ 32 weeks’ gestation and/or ≤1500 g birthweight. Total RNA from EEIC were processed for genome-wide expression analysis., [Results] Principal component analysis and unsupervised hierarchical clustering analysis revealed two clustered groups corresponding to the OMM and DHM groups that showed differences in the gene expression profile in 1629 transcripts. The OMM group overexpressed lactalbumin alpha gene (LALBA), Cytochrome C oxidase subunit I gene (COX1) and caseins kappa gene (CSN3), beta gene (CSN2) and alpha gene (CSN1S1) and underexpressed Neutrophil Cytosolic Factor 1 gene (NCF1) compared to the DHM group., [Conclusions] The transcriptomic analysis of EEIC showed that OMM induced a differential expression of specific genes that may contribute to a more efficient response to a pro-oxidant challenge early in the postnatal period when preterm infants are at a higher risk of oxidative stress. The use of OMM should be strongly promoted in preterm infants., A.P.-L.: A.G.-R., S.L.-P. and J.K. enjoy research grants CM18/00165, CM16/00174, FI18/0131, CP16/00034 respectively from the Instituto de Investigación Sanitaria Carlos III (Ministry of Science, Innovation and Universities); M.C.C. acknowledges the support from ERC Starting Grant 639226-MAMI from the European Union and also, the Spanish Government of Economy and Competitiveness (MINECO) (AGL2015-707487-P grant). MV a full grant from the RETICS funded by the PN 2018-2021 (Spain), ISCIII- Sub-Directorate General for Research Assessment and Promotion and the European Regional Development Fund (FEDER), reference RD16/0022/0001 and PI17/0131 grant for the IIS Carlos III (Ministry of Science, Innovation and Universities)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Microbiome-metabolome signatures in mice genetically prone to develop dementia, fed a normal or fatty diet

  • Sanguinetti, Elena
  • Collado, María Carmen
  • Marrachelli, Vannina G.
  • Monleón, Daniel
  • Selma Royo, Marta
  • Pardo Tendero, M.M.
  • Burchielli, S.
  • Iozzo, P.
Cognitive decline, obesity and gut dysfunction or microbial dysbiosis occur in association. Our aim was to identify gut microbiota-metabolomics signatures preceding dementia in genetically prone (3xtg) mice, with and without superimposed high-fat diet. We examined the composition and diversity of their gut microbiota, and serum and faecal metabolites. 3xtg mice showed brain hypometabolism typical of pre-demented stage, and lacked the physiological bacterial diversity between caecum and colon seen in controls. Cluster analyses revealed distinct profiles of microbiota, and serum and fecal metabolome across groups. Elevation in Firmicutes-to-Bacteroidetes abundance, and exclusive presence of Turicibacteraceae, Christensenellaceae, Anaeroplasmataceae and Ruminococcaceae, and lack of Bifidobacteriaceae, were also observed. Metabolome analysis revealed a deficiency in unsaturated fatty acids and choline, and an overabundance in ketone bodies, lactate, amino acids, TMA and TMAO in 3xtg mice, with additive effects of high-fat diet. These metabolic alterations were correlated with high prevalence of Enterococcaceae, Staphylococcus, Roseburia, Coprobacillus and Dorea, and low prevalence of S24.7, rc4.4 and Bifidobacterium, which in turn related to cognitive impairment and cerebral hypometabolism. Our results indicate an effect of transgenic background on gut microbiome-metabolome, enhanced by high-fat diet. The resulting profiles may precede overt cognitive impairment, suggesting their predictive or risk-stratifying potential., This work was supported by the Ministry of Economy, Industry and Competitiveness of Spain (MINECO-Spanish Government, grant numbers SAF2014–52875R to DM, and AGL2015–707487-P to MCC), Instituto de Salud Carlos III and co-funded by ‘FEDER’ (grant number PIE15/00013 to DM), and the European DORIAN-Health-FP7 project (GA 278603 to PI)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Two-Week Aflibercept or Erlotinib Administration Does Not Induce Changes in Intestinal Morphology in Male Sprague–Dawley Rats But Aflibercept Affects Serum and Urine Metabolic Profiles

  • Forsgård, Richard A.
  • Marrachelli, Vannina G.
  • Lindén, Jere
  • Frías, Rafael
  • Collado, María Carmen
  • Korpela, Riitta
  • Monleón, Daniel
  • Spillmann, Thomas
  • Österlund, Pia
Gastrointestinal toxicity is a frequently observed adverse event during cancer treatment with traditional chemotherapeutics. Currently, traditional chemotherapeutics are often combined with targeted biologic agents. These biologics, however, possess a distinct toxicity profile, and they may also exacerbate the adverse effects of traditional chemotherapeutics. In this study, we aimed to characterize the gastrointestinal and metabolic changes after a 2-week treatment period with aflibercept, an antiangiogenic VEGFR decoy, and with erlotinib, a tyrosine-kinase inhibitor. Male rats were treated either with aflibercept or erlotinib for 2 weeks. During the 2-week treatment period, the animals in the aflibercept group received two subcutaneous doses of 25 mg/kg aflibercept. The erlotinib group got 10 mg/kg of erlotinib by oral gavage every other day. The control groups were treated similarly but received either saline injections or oral gavage of water. Intestinal toxicity was assessed by measuring intestinal permeability and by histological analyses of intestinal tissues. Metabolic changes were measured with H nuclear magnetic resonance in serum and urine. Neither aflibercept nor erlotinib induced changes in intestinal permeability or intestinal tissue morphology. However, aflibercept treatment resulted in stunted body weight gain and altered choline, amino acid, and lipid metabolism. Two-week treatment with aflibercept or erlotinib alone does not induce observable changes in gastrointestinal morphology and function. However, observed aflibercept-treatment related metabolic changes suggest alterations in intestinal microbiota, nutrient intake, and adipose tissue function. The metabolic changes are also interesting in respect to the systemic effects of aflibercept and their possible associations with adverse events caused by aflibercept administration., The study received funding from the Cancer Society of Finland, Finska Läkaresällskapet, Foundation of Clinical Chemistry Research, and Biomedicum Helsinki Foundation. We gratefully acknowledge the Ministry of Economy and Competitiveness of Spain (SAF2014-52875R) and Instituto de Salud Carlos III and FEDER (grant number PIE15/00013) for co-funding the study. We also gratefully acknowledge the Ministry of Science, Innovation and Universities (PCIN-2017-117) and the EU Joint Programming Initiative ‘A Healthy Diet for a Healthy Life’ (JPI HDHL INTIMIC-085). M. C. C. would like to acknowledge the support of the Spanish Government of Economy and Competitiveness (MINECO, ref. AGL2015-707487-P).